CASI Pharmaceuticals Inc is a holding company principally engaged in developing and commercializing innovative therapeutics and pharmaceutical products. The Companyâ€™s main business is engaged in acquiring, developing and commercializing products that augment its hematology oncology, autoimmune and organ transplant rejection therapeutic area focus as well as other unmet medical need. The Companyâ€™s main products include EVOMELA (Melphalan for Injection), FOLOTYN (Pralatrexate), CNCT19, BI-1206, CB-5339, CID-103, Thiotepa and others. The Company mainly conducts its business in the domestic market.

Employees

-

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
10/07/26	$0.1451	+0.08%	189
09/07/26	$0.1450	-	1,865
08/07/26	$0.000000	-100.00%	52
07/07/26	$0.1317	-34.13%	190
06/07/26	$0.1999	+36.11%	800

Delayed Quote Nasdaq

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

1

Last Close Price

0.1451USD

Average target price

4.000USD

Spread / Average Target

+2,656.72%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Nasdaq Other stock markets 18:34:50 10/07/2026 +03			5-day change	1st Jan Change
0.1451 ^USD	+0.08%		-1.23%	-82.93%

06-02	CASI Pharmaceuticals, Inc. Announces Resignation of Barbara Krebs-Pohl as Director, Effective May 31, 2026	CI
05-15	CASI Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI

Market Cap	2.98M 2.61M 2.41M 2.22M 4.22M 284M 4.29M 28.75M 11.29M 140M 11.2M 10.96M 482M	P/E 2026 *	-0.1x	P/E 2027 *	-0.1x
Enterprise Value	2.98M 2.61M 2.41M 2.22M 4.22M 284M 4.29M 28.75M 11.29M 140M 11.2M 10.96M 482M	EV / Sales 2026 *	-	EV / Sales 2027 *	-
Free-Float	53.62%	Yield 2026 *	-	Yield 2027 *	-

06-02	CASI Pharmaceuticals, Inc. Announces Resignation of Barbara Krebs-Pohl as Director, Effective May 31, 2026	CI
05-15	CASI Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
05-15	CASI Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt	CI
04-20	CASI Pharmaceuticals, Inc. announced that it has received $20 million in funding from ETP Global III Fund LP	CI
04-20	CASI Pharmaceuticals, Inc. Announces Termination of Dr. Alexander A. Zukiwski, MD as Global Chief Medical Officer, Effective April 20, 2026	CI
03-03	CASI Pharmaceuticals, Inc. Announces CEO Changes	CI
03-03	Casi Pharmaceuticals, Inc. Announces Resignation of Director David Cory, Effective March 31, 2026	CI

1 week	-1.23%
Current month	-14.65%
1 month	+31.91%
3 months	+0.48%
6 months	-86.81%
Current year	-82.93%

CASI Pharmaceuticals, Inc. Stock Nasdaq

Stocks

CASI

KYG1933S1012

Pharmaceuticals

Valuation: CASI Pharmaceuticals, Inc.

Chart: CASI Pharmaceuticals, Inc.

Latest news : CASI Pharmaceuticals, Inc.

Press Releases: CASI Pharmaceuticals, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: CASI Pharmaceuticals, Inc.

Other Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Quarterly revenue - Rate of surprise

1 week	0.13	0.2
1 month	0.12	0.35
3 years	0.05	8.48
5 years	0.05	17.4
10 years	0.05	88.92

Manager	Title	Age	Since
David Cory CEO	Chief Executive Officer	62	21/07/2025
Kun Qian DFI	Director of Finance/CFO	44	16/05/2025
Chun Hua Wang COO	Chief Operating Officer	54	01/01/2017

Director	Title	Age	Since
Yue Wu BRD	Director/Board Member	62	01/04/2013
Zhen Bo Su BRD	Director/Board Member	50	21/03/2023
Thomas Folinsbee BRD	Director/Board Member	59	21/03/2023

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
CASI PHARMACEUTICALS, INC.	+0.08%	-1.23%	-89.85%	-94.67%	2.98M
ELI LILLY AND COMPANY	-2.33%	-2.09%	+50.33%	+162.29%	1,060B
JOHNSON & JOHNSON	-0.82%	-2.30%	+62.97%	+61.11%	619B
ABBVIE INC.	-0.73%	-4.98%	+27.22%	+84.46%	438B
ROCHE HOLDING AG	+0.33%	-1.17%	+27.98%	+26.90%	333B
NOVARTIS AG	-0.02%	-2.85%	+25.27%	+44.88%	282B
ASTRAZENECA PLC	-3.89%	-11.22%	+20.78%	+26.07%	267B
NOVO NORDISK A/S	+0.66%	-1.42%	-29.26%	-39.30%	218B
AMGEN INC.	-0.06%	-2.88%	+20.98%	+61.70%	196B
GILEAD SCIENCES, INC.	-3.72%	-1.10%	+13.35%	+71.53%	161B
Average	-0.89%	-3.25%	+12.98%	+40.50%	397.1B
Weighted average by Cap.	-0.56%	-2.96%	+35.28%	+81.27%

	2026 *	2027 *
Net sales	-	-
Net income	-24.73M -21.63M -19.95M -18.42M -34.96M -2.36B -35.55M -238M -93.6M -1.16B -92.84M -90.82M -3.99B	-26.51M -23.19M -21.39M -19.75M -37.48M -2.53B -38.11M -256M -100M -1.25B -99.54M -97.37M -4.28B
Net Debt	-	-